NFL BIOSCIENCES
Research
Paris, Fr
7 employees
- Employees
- 7
NFL BIOSCIENCES Overview
- Headquarters
- Paris, Fr
- Website
- smokefreetherapeutics.com
- Industry
- Research
- Employees
- 7
- Founded
- 2009
- Funding
- 1.4M
About NFL BIOSCIENCES
NFL BIOSCIENCES clinically develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. It is delivered via two simple subcutaneous injections, administered one week apart, making patient compliance a breeze. There exists vast anecdotal evidence, from more than 10,000 smokers treated off-label in France with a predecessor product developed by the Pasteur Institute, that NFL-101 is safe and efficacious for total smoking cessation at twelve months. A Phase 1 clinical trial that reported data in 2017 confirmed safety and efficacy in smokers willing and trying to quit, in terms of total cessation at twelve months as well as reduction without compensatory over-smoking.
NFL BIOSCIENCES Contact Details
- People in AeroLeads
- 4
NFL BIOSCIENCES Org Chart
Sample employees and titles| Name | Title | Location | Contact |
|---|---|---|---|
| Bruno Lafont | Co-founder and CEO at Nfl Biosciences |
View
|
|
| Guillaume Audema | Financial Director Chez Nfl Biosciences | Greater Montpellier Metropolitan Area, France |
View
|
| Darshana Dhar | Retired at Nfl Biosciences | Delhi, India |
View
|
| Maaz Malik | Working in National Food Company |
View
|
Employees by Management Level
Individual contributor
2 profiles
Executive
1 profile
Director
1 profile
Compare Similar Companies to NFL BIOSCIENCES
Transgene
Biotechnology
GENFIT
Biotechnology
Innate Pharma
Biotechnology Research
Medincell
Pharmaceutical Manufacturing
Nanobiotix
Nanotechnology Research
ADOCIA
Biotechnology Research
Abivax
Biotechnology
Sensorion
Biotechnology Research
Nicox
Pharmaceutical Manufacturing
Theranexus
Biotechnology Research